Mercia’s Life Sciences’ portfolio: Value and Innovation

Life Sciences investments accounted for seven out of Mercia’s top 20 direct investments as at 31 March 2020 and their cumulative fair value of £28.6million represented 32.7% of the total portfolio by value.

All of Mercia’s Life Sciences direct investments originated from our third-party managed funds and in addition to these investments, We have a further c.40 Life Sciences investments across its third-party managed funds.

In the current financial year to date £4.2million has been invested into six Life Sciences direct investments, with a further £1.6million invested by Mercia’s managed funds.

Mark Payton, Chief Executive Officer at Mercia, commented:

“The Life Sciences sector represents a significant growth area in the UK’s regions and is well positioned to benefit from current trends. We are excited by the progress we are seeing in both our direct investments and managed funds, and the potential of our portfolio demonstrates the value and innovation in the UK healthcare sector. Today’s update is an important indicator that the life sciences’ community is predominantly located outside of London and that not only is it resilient, but it is fast growing.

“Mercia has demonstrated its ability to identify investment opportunities to which others do not have access. By continuing to invest and nurture early-stage regional Life Sciences businesses, we make it possible for the UK’s technology industry to have a real impact in tackling global issues, build regional employment and create demonstrable shareholder value.”


Read the full RNS Reach here.